At what age does gynaecomastia go away is a common concern for adolescent boys and their families, as well as adult men experiencing persistent breast tissue enlargement. Gynaecomastia — the benign growth of glandular breast tissue in males — is most frequently a temporary feature of puberty, but its duration and likelihood of resolution vary considerably depending on age, underlying cause, and how long the condition has been present. This article explains the typical timeline for resolution, the factors that influence how long gynaecomastia lasts, when to seek medical advice, and the treatment options available through the NHS.

What Is Gynaecomastia and Why Does It Develop?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an imbalance between oestrogen and androgen activity. Common causes include puberty, certain medications, and underlying conditions such as hypogonadism or hyperthyroidism.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular growth and is more commonly seen in individuals with higher body weight. Understanding the difference is important, as the two conditions have different causes and management pathways. Weight loss may improve the appearance of pseudogynaecomastia, but established glandular tissue in true gynaecomastia is unlikely to regress through weight reduction alone.

The condition develops due to an imbalance between oestrogen and androgen (testosterone) activity in breast tissue. Oestrogens stimulate breast tissue growth, whilst androgens suppress it. When this balance shifts — whether due to hormonal fluctuations, medications, or underlying health conditions — glandular tissue can proliferate.

This hormonal imbalance can arise from several causes:

• Puberty: A temporary surge in oestrogen relative to testosterone is the most common cause in adolescents

• Neonatal period: Transient gynaecomastia in newborns due to maternal oestrogens is a normal variant that resolves spontaneously within a few weeks

• Medications: A number of medicines are associated with gynaecomastia, including anti-androgens (e.g., bicalutamide), spironolactone, finasteride, dutasteride, GnRH analogues, oestrogens, anabolic steroids, digoxin, cimetidine, ketoconazole, and certain antiretrovirals (e.g., efavirenz). Always discuss any concerns about prescribed medicines with your GP or pharmacist before making any changes

• Medical conditions: Including hypogonadism (including Klinefelter syndrome), hyperthyroidism, liver cirrhosis, and renal failure. hCG-secreting testicular tumours are an important cause to exclude, particularly in younger men

• Recreational substances: Excessive alcohol consumption (via liver disease) and anabolic steroids have well-established associations; the evidence linking cannabis to gynaecomastia is based on low-quality, associative data and should be interpreted cautiously

In many cases, particularly in adolescent boys, no underlying pathology is identified and the condition is considered physiological. However, a thorough clinical assessment is always warranted to rule out secondary causes, particularly when the presentation is atypical or accompanied by other symptoms.

It is important to note that whilst true gynaecomastia is not generally associated with an increased risk of male breast cancer, certain underlying conditions — such as Klinefelter syndrome — do carry a higher risk. Any new, asymmetric, hard, or rapidly changing breast lump should always be evaluated by a clinician promptly, in line with NHS guidance.

At What Age Does Gynaecomastia Typically Resolve?

Pubertal gynaecomastia typically resolves within 6 to 24 months of onset, with most cases resolving by late adolescence. Spontaneous resolution becomes significantly less likely if the condition persists beyond age 18 to 20.

The age at which gynaecomastia resolves depends largely on its underlying cause, but the most common form — pubertal gynaecomastia — tends to follow a predictable natural course. In adolescent males, breast tissue enlargement typically begins between the ages of 10 and 14, coinciding with the onset of puberty and the associated hormonal changes. Peak prevalence is generally observed around the ages of 13 to 14.

It is worth noting that gynaecomastia occurring before puberty (prepubertal onset) is uncommon and should prompt prompt specialist assessment, as it may indicate an underlying endocrine or other medical condition.

For the majority of boys, pubertal gynaecomastia is self-limiting. According to NICE CKS and NHS guidance, most cases resolve spontaneously within 6 to 24 months of onset, without any medical intervention, and the majority have resolved by late adolescence. As testosterone levels stabilise and the androgen-to-oestrogen ratio normalises, breast tissue typically regresses. For many young males, gynaecomastia is therefore a temporary feature of normal development rather than a persistent medical condition.

However, if gynaecomastia persists beyond the age of 18 to 20, spontaneous resolution becomes significantly less likely. Over time, fibrous tissue can replace the initial glandular proliferation — the precise timing of this process varies between individuals and the evidence base is limited — making the breast tissue more established and less likely to regress on its own. In adult men, gynaecomastia may persist indefinitely without treatment, particularly if the underlying cause (such as medication use or a hormonal condition) is not addressed.

Gynaecomastia can also occur in older men, particularly those aged 50 to 80, due to age-related declines in testosterone. In this population, spontaneous resolution is less common, and investigation to identify a reversible cause is particularly important.

Factors That Affect How Long Gynaecomastia Lasts

Duration of the condition is the most significant factor — gynaecomastia present for less than 12 months is more likely to regress spontaneously, whereas fibrosis after 12 to 24 months makes resolution without intervention considerably less likely.

Whilst age is a key determinant, several other factors influence whether gynaecomastia resolves naturally or persists over time. Understanding these variables can help both patients and clinicians make informed decisions about monitoring versus active treatment.

Duration of the condition is one of the most significant factors. Gynaecomastia that has been present for less than 12 months is more likely to regress spontaneously, as the tissue remains predominantly glandular and responsive to hormonal changes. Beyond 12 to 24 months, fibrosis tends to set in, making resolution without intervention considerably less likely.

Underlying cause also plays a critical role:

• If gynaecomastia is drug-induced, discontinuing or switching the offending medication (always under medical supervision — do not stop prescribed medicines without advice) may lead to gradual improvement. However, regression following withdrawal of a causative medicine can take several months and may be incomplete, particularly if the condition has been longstanding

• If caused by a treatable medical condition such as hyperthyroidism or hypogonadism, addressing the primary condition can result in improvement

• Idiopathic or pubertal cases are most likely to resolve without treatment

Severity of tissue enlargement is also relevant. Mild cases are more likely to resolve than moderate or severe cases, where the volume of glandular tissue is greater and fibrosis more advanced. Your clinician may use a grading system (such as the Simon classification) to assess severity and guide management decisions.

Lifestyle factors such as anabolic steroid use and excessive alcohol consumption (which can impair liver function and alter hormone metabolism) can perpetuate hormonal imbalance and delay or prevent resolution. Addressing these factors is an important part of management. Obesity can worsen the condition by increasing peripheral conversion of androgens to oestrogens in adipose tissue; weight management may therefore support improvement in the adipose component, though established glandular tissue is unlikely to regress with weight loss alone.

Psychological impact should not be underestimated. Persistent gynaecomastia can significantly affect self-esteem and quality of life, particularly in adolescents, and this should be acknowledged and addressed as part of clinical care.

When to See a GP About Breast Tissue Changes

You should see a GP promptly if you notice a unilateral, hard, or rapidly changing breast lump, nipple discharge, or associated testicular changes, as these may indicate a condition requiring urgent investigation under NICE NG12 guidance.

Whilst pubertal gynaecomastia is usually benign and self-resolving, there are specific circumstances in which it is important to seek a medical assessment promptly. A GP can help distinguish physiological gynaecomastia from conditions requiring further investigation or treatment.

You should contact your GP if:

• Breast tissue enlargement is present in only one breast (unilateral), or one side is significantly larger than the other

• There is a hard, irregular, or fixed lump within the breast tissue

• The nipple is discharging fluid, particularly if bloodstained

• There is skin dimpling, puckering, or changes to the nipple

• Breast changes are accompanied by pain, tenderness, or rapid growth

• You notice a testicular lump, swelling, or pain (which may indicate an hCG-secreting tumour requiring urgent assessment)

• You notice enlarged lymph nodes in the armpit

• Gynaecomastia develops before puberty — this is uncommon and warrants prompt specialist evaluation

• Gynaecomastia develops in an adult male with no obvious cause

• The condition persists beyond two years or beyond the age of 18 without improvement

• There are associated symptoms such as fatigue, weight changes, or reduced libido that may suggest an underlying hormonal condition

Male breast cancer, whilst rare — accounting for less than 1% of all breast cancers in the UK — can present with breast tissue changes and should always be excluded in atypical presentations. In line with NICE NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent suspected cancer (two-week-wait) referral for any male presenting with a suspicious breast lump or nipple change.

Your GP will typically take a full medical and medication history, perform a clinical examination (including examination of the testes), and may arrange blood tests to assess hormone levels (including testosterone, LH, FSH, oestradiol, and prolactin), thyroid function, and liver and renal function. Where a testicular tumour is suspected, hCG and AFP (alpha-fetoprotein) should also be measured. Breast imaging is not routinely required in typical pubertal gynaecomastia but may be arranged by specialists if the diagnosis is uncertain. Referral to an endocrinologist or breast surgeon may follow depending on findings. Early assessment not only provides reassurance but ensures that any reversible or treatable cause is identified promptly.

Treatment Options Available on the NHS

Watchful waiting with reassurance is the standard NHS approach for pubertal gynaecomastia; surgical mastectomy is the most definitive treatment for established cases, with NHS funding subject to local ICB eligibility criteria.

For the majority of adolescents with pubertal gynaecomastia, active treatment is not required. A period of watchful waiting with reassurance is the standard approach recommended by NICE CKS and NHS guidance. Regular follow-up appointments allow clinicians to monitor progression and provide psychological support, which is particularly valuable for younger patients experiencing distress.

Where an underlying cause is identified, treating the primary condition is the first-line approach. This may involve:

• Reviewing and adjusting medications that are contributing to hormonal imbalance (always under medical supervision — do not stop prescribed medicines without advice)

• Managing confirmed hypogonadism with testosterone replacement therapy, where clinically appropriate. It should be noted that testosterone therapy should only be used for confirmed hypogonadism under specialist supervision; in some cases it may initially worsen gynaecomastia through peripheral conversion (aromatisation) to oestrogen

• Addressing thyroid or liver disease through established treatment pathways

Pharmacological treatment is not routinely recommended for gynaecomastia on the NHS. In specific cases — particularly where the condition is causing significant psychological distress, is of recent onset, and conservative measures have not helped — a specialist may consider off-label use of the following medicines:

• Tamoxifen (a selective oestrogen receptor modulator, or SERM): Some evidence suggests it can reduce breast tissue volume, particularly in early-stage gynaecomastia

• Raloxifene: Another SERM that has shown some benefit in clinical studies

These medicines are used off-label for this indication in the UK, the evidence base is limited, and they would be initiated by a specialist rather than in primary care. Both tamoxifen and raloxifene carry risks that must be discussed before starting treatment, including an increased risk of venous thromboembolism (blood clots), hot flushes, and leg swelling. Patients should seek urgent medical attention if they develop symptoms such as leg pain, swelling, breathlessness, or chest pain whilst taking these medicines. If you experience any suspected side effects from any medicine, you can report these via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Surgical treatment — specifically subcutaneous mastectomy or liposuction-assisted mastectomy — is the most definitive option for established, fibrotic gynaecomastia that has not responded to other measures. NHS funding for surgery is subject to local Integrated Care Board (ICB) policies, which typically require documented significant psychological impact, persistence of the condition despite conservative management, stable weight, and smoking cessation prior to surgery. Eligibility criteria vary between ICBs, and your GP can advise on local arrangements. Private surgical options are available for those who do not meet NHS criteria. A referral to a breast surgeon or plastic surgeon can be requested through your GP if surgery is being considered.

Frequently Asked Questions